Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin.

Czer LS, Bateman TM, Gray RJ, Raymond M, Stewart ME, Lee S, Goldfinger D, Chaux A, Matloff JM

Journal of the American College of Cardiology1 May 1987Cited by 78 (Europe PMC)

PMID3571753DOI10.1016/s0735-1097(87)80319-4PepBankPUB-03571753

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients bleeding after bypass, desmopressin reduced blood product use versus controls (15 +/- 13 versus 29 +/- 19 units/patient, p less than 0.05).
In plain wordsIn patients bleeding after bypass, desmopressin reduced blood product use compared with controls.
Peptide
Desmopressin
Outcome
DecreaseBlood product use
Study
n = 39
Comparator
No desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Blood product use, mean
29 units/patient
control group (no desmopressin)
Blood product use, SD
19 units/patient
control group (no desmopressin)
Blood product use, mean
15 units/patient
desmopressin group
Blood product use, SD
13 units/patient
desmopressin group
Source sentences
Summary
Compared with the control group, the patients receiving desmopressin (20 micrograms; mean 0.3 micrograms/kg) utilized fewer blood products (29 +/- 19 versus 15 +/- 13 units/patient; p less than 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175301
02HumanNon-randomized trialEfficacy outcome
In patients bleeding after bypass, desmopressin reduced platelet use versus controls (4 +/- 7 versus 12 +/- 9 units/patient, p = 0.004).
In plain wordsIn patients bleeding after bypass, desmopressin reduced platelet use compared with controls.
Peptide
Desmopressin
Outcome
DecreasePlatelet product use
Study
n = 39
Comparator
No desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Platelet use, mean
12 units/patient
control group (no desmopressin)
Platelet use, SD
9 units/patient
control group (no desmopressin)
Platelet use, mean
4 units/patient
desmopressin group
Platelet use, SD
7 units/patient
desmopressin group
Source sentences
Summary
especially platelets (12 +/- 9 versus 4 +/- 7 units/patient; p = 0.004)
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175302
03HumanNon-randomized trialEfficacy outcome
In patients bleeding after bypass, desmopressin and controls achieved similarly effective reductions in mediastinal bleeding (4.8- and 4.3-fold, p = 0.001 for both).
In plain wordsIn patients bleeding after bypass, bleeding fell by a similar amount in the desmopressin group and in the control group.
Peptide
Desmopressin
Outcome
Direction not reportedMediastinal bleeding reduction
Study
n = 39
Comparator
No desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Mediastinal bleeding reduction
4.8 fold
first value listed; source does not say which group
Mediastinal bleeding reduction
4.3 fold
second value listed; source does not say which group
Source sentences
Summary
while achieving a similarly effective reduction in mediastinal bleeding (4.8- and 4.3-fold, p = 0.001 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175303
04HumanNon-randomized trialEfficacy outcome
In patients bleeding after bypass, desmopressin shortened bleeding time from 17 to 12.5 minutes within 1 hour (p less than 0.05).
In plain wordsIn patients bleeding after bypass, desmopressin shortened bleeding time compared with baseline.
Peptide
Desmopressin
Outcome
DecreaseTemplate bleeding time
Study
n = 23
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Template bleeding time
17 minutes
before desmopressin
Template bleeding time
12.5 minutes
within 1 hour after desmopressin infusion
Source sentences
Summary
Severe platelet dysfunction was partially corrected within 1 hour after desmopressin infusion, during which interval no blood products were administered: the template bleeding time shortened (from 17 to 12.5 minutes, p less than 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175304
05HumanNon-randomized trialMechanism
In patients bleeding after bypass, platelet counts remained unchanged after desmopressin (96 +/- 35 and 105 +/- 31 X 10(3)/mm3, p = NS).
In plain wordsIn patients bleeding after bypass, desmopressin did not change platelet counts compared with baseline.
Peptide
Desmopressin
Outcome
No significant changePlatelet count
Study
n = 23
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
Platelet count
96 X 10(3)/mm3
first value listed
Platelet count, SD
35 X 10(3)/mm3
first value listed
Platelet count
105 X 10(3)/mm3
second value listed
Platelet count, SD
31 X 10(3)/mm3
second value listed
Source sentences
Summary
whereas the platelet count remained unchanged (at 96 +/- 35 and 105 +/- 31 X 10(3)/mm3, p = NS).
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175305
06HumanNon-randomized trialMechanism
In patients bleeding after bypass, desmopressin increased VIII:C from 0.97 +/- 0.43 to 1.52 +/- 0.74 units/ml (p less than 0.05).
In plain wordsIn patients bleeding after bypass, desmopressin increased clotting factor VIII activity compared with baseline.
Peptide
Desmopressin
Outcome
IncreaseFactor VIII procoagulant activity
Study
n = 23
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
VIII:C plasma level
0.97 units/ml
before desmopressin
VIII:C plasma level, SD
0.43 units/ml
before desmopressin
VIII:C plasma level
1.52 units/ml
after desmopressin
VIII:C plasma level, SD
0.74 units/ml
after desmopressin
Source sentences
Summary
The plasma levels of two factor VIII components increased: procoagulant activity (VIII:C) from 0.97 +/- 0.43 to 1.52 +/- 0.74 units/ml (p less than 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175306
07HumanNon-randomized trialMechanism
In patients bleeding after bypass, desmopressin increased VIII:vWF from 1.28 to 1.78 units/ml (p less than 0.05).
In plain wordsIn patients bleeding after bypass, desmopressin increased von Willebrand factor compared with baseline.
Peptide
Desmopressin
Outcome
Increasevon Willebrand factor
Study
n = 23
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Measurements
VIII:vWF plasma level
1.28 units/ml
before desmopressin
VIII:vWF plasma level
1.78 units/ml
after desmopressin
Source sentences
Summary
and von Willebrand factor (VIII:vWF) from 1.28 to 1.78 units/ml (p less than 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175307
08HumanNon-randomized trialMechanism
In patients bleeding after bypass, factor VIII component increases after desmopressin correlated with bleeding-time shortening (p less than 0.01).
In plain wordsIn patients bleeding after bypass, clotting factor increases after desmopressin correlated with shorter bleeding times.
Peptide
Desmopressin
Outcome
Not applicableFactor increases correlation with bleeding-time shortening
Study
n = 23
Outcome group
Bleeding and clotting · Whole body
Studied dose
20 micrograms; mean 0.3 micrograms/kg · intravenousAs given in this study (human).
Source sentences
Summary
these increases correlated with the shortening of the bleeding time (p less than 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Because desmopressin acetate (a synthetic analogue of vasopressin) shortens bleeding time in a variety of platelet disorders, a controlled clinical trial of intravenous desmopressin was performed in 39 patients with excessive mediastinal bleeding (greater than 100 ml/h) and a prolonged template blee…
Summary · context
Twenty-three desmopressin recipients and 16 control patients (no desmopressin) were similar in surgical procedure, pump time, platelet count, template bleeding time and amount of bleeding before therapy (p = NS).
Report a problemFND-0357175308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.